(All fields required)
Please enter a valid email.
Please enter your name.
J. Pablo Abonia, MD Interim Director, Registry for Eosinophilic Disorders (REGID)
Interim Director, Registry for Eosinophilic Disorders (REGID)
Associate Professor, UC Department of Pediatrics
Eosinophilic and mast cell disorders; immunodeficiency
J. Pablo Abonia, MD, provides the bulk of the clinical allergy care for patients with eosinophilic disease. He is currently involved in a multicenter clinical research trial of anti-IL5 (reslizumab) for patients with eosinophilic esophagitis. His research focuses on mining the research databanks (patient characteristics, tissue samples, RNA and DNA) to elucidate the mechanisms, diagnosis and treatment of eosinophilic esophagitis, and he is the Interim Director of the Registry for Eosinophilic Disorders (REGID). He is particularly interested in the role of mast cells in eosinophilic esophagitis.
MD: University of Buffalo, Buffalo, NY, 1997.
Residency: Pediatrics, Children's Hospital of Buffalo, Buffalo, NY, 2000.
Certification: American Board of Pediatrics, 2001; American Board of Allergy and Immunology, 2003.
Abonia JP, Rothenberg ME. Eosinophilic esophagitis: rapidly advancing insights. Annu Rev Med. 2012;63:421-34.
Spergel JM, Rothenberg ME, Collins MH, Furuta GT, Markowitz JE, Fuchs G 3rd, O'Gorman MA, Abonia JP, Young J, Henkel T, Wilkins HJ, Liacouras CA. Reslizumab in children and adolescents with eosinophilic esophagitis: results of a double-blind, randomized, placebo-controlled trial. J Allergy Clin Immunol. 2012 Feb;129(2):456-63.
Lu TX, Sherrill JD, Wen T, Plassard AJ, Besse JA, Abonia JP, Franciosi JP, Putnam PE, Eby M, Martin LJ, Aronow BJ, Rothenberg ME. MicroRNA signature in patients with eosinophilic esophagitis, reversibility with glucocorticoids, and assessment as disease biomarkers. J Allergy Clin Immunol. 2012 Apr;129(4):1064-75.
Henderson CJ, Abonia JP, King EC, Putnam PE, Collins MH, Franciosi JP, Rothenberg ME. Comparative dietary therapy effectiveness in remission of pediatric eosinophilic esophagitis. J Allergy Clin Immunol. 2012 Jun;129(6):1570-8.
Franciosi JP, Hommel KA, DeBrosse CW, Greenberg AB, Greenler AJ, Abonia JP, Rothenberg ME, Varni JW. Quality of life in paediatric eosinophilic oesophagitis: what is important to patients? Child Care Health Dev. 2012 Jul;38(4):477-83.
Franciosi JP, Hommel KA, Greenberg AB, Debrosse CW, Greenler AJ, Abonia JP, Rothenberg ME, Varni JW. Development of the Pediatric Quality of Life Inventory Eosinophilic Esophagitis Module items: qualitative methods. BMC Gastroenterol. 2012 Sep 25;12(1):135.
Abonia JP, Putnam PE. Mepolizumab in eosinophilic disorders. Expert Rev Clin Immunol. 2011 Jul;7(4):411-7.
Debrosse CW, Franciosi JP, King EC, Buckmeier Butz BK, Greenberg AB, Collins MH, Abonia JP, Assa'ad A, Putnam PE, Rothenberg ME. Long-term outcomes in pediatric-onset esophageal eosinophilia. J Allergy Clin Immunol. 2011 Jul;128(1):132-8.Abonia JP, Castells M. Drug allergy in pediatric patients. Pediatr Ann. 2011 Apr;40(4):200-4.
Franciosi JP, Hommel KA, DeBrosse CW, Greenberg AB, Greenler AJ, Abonia JP, Rothenberg ME, Varni JW. Development of a validated patient-reported symptom metric for pediatric eosinophilic esophagitis: qualitative methods. BMC Gastroenterol. 2011 Nov 18;11:126.
Amal H. Assa'ad, MD Associate Director, Division of Allergy and Immunology
Associate Director, Division of Allergy and Immunology
Director of Clinical Services, Division of Allergy and Immunology
Professor, UC Department of Pediatrics
MBBCh (MD): Ain Shams University, Cairo, Egypt 1978.
MS: Ain Shams University, Cairo, Egypt, 1982.
Residency: Internal Medicine/Pediatrics, Michigan State University, Hurley Medical Center, Flint, Mich.; Internal Medicine/Pediatrics, Wright State University, Dayton, Ohio, 1990-1992.Fellowship: Allergy/Clinical Immunology, University of Texas Health Science Center, San Antonio, Texas, 1986-1987; Allergy/Clinical Immunology, Children's Hospital Medical Center, Cincinnati, Ohio, 1992-1995.Certification: American Board of Internal Medicine, 1992; American Board of Pediatrics, 1992; American Board of Allergy and Immunology, 1995.
Amin MR, Khoury JC, Assa’ad AH. Food-specific serum immunoglobulin E measurements in children presenting with food allergy. Ann Allergy Asthma Immunol. 2014; 112(2): 121-5.
Fiocchi A, Annunziato F, Assa'ad A, et al. The management of paediatric allergy: not everybody's cup of tea--10-11th February 2012. Curr Opin Allergy Clin Immunol, 2013; 13 Suppl 1, S1-50.
Fleischer D, Spergel J, Assa’ad A, Pongracic J. Primary Prevention of Allergic Disease Through Nutritional Interventions. J Allergy Clin Immunol. In Practice, 2013; 1(1): 29-36.
Assa'ad A, Fiocchi A. Guidelines change the diagnostic process of cow milk food allergy: problem- based learning. Curr Opin Allergy Clin Immunol. 2012; 12:564–569.
Butsch Kovacic M, Biagini Myers JM, Lindsey M, Patterson T, Sauter S, Ericksen MB, Ryan P, Assa'ad A, et al. The Greater Cincinnati Pediatric Clinic Repository: A Novel Framework for Childhood Asthma and Allergy Research. Pediatr Allergy Immunol Pulmonol. 2012; 25(2): 104-113.
Uygungil B, Assa'ad A, et al. Immunodeficiency: a problem with the faucet or the drain?Ann Allergy Asthma Immunol. 2011; 107(6): p. 547-9.
Sackesen C, Assa'ad A, et al. Cow's milk allergy as a global challenge. Curr Opin Allergy Clin Immunol. 2011(3): 243-248.
Burks AW, Jones SM, Boyce JA, Sicherer SH, Wood RA, Assa'ad A, Sampson HA. NIAID-Sponsored 2010 Guidelines for Managing Food Allergy: Applications in the Pediatric Population. Pediatrics. 2011; 128(5): 955-965.
Boyce JA, Assa'ad A, et al. Guidelines for the diagnosis and management of food allergy in the United States: summary of the NIAID-sponsored expert panel report. Nutr Res. 2011; 31(1): 61-75.
Assa'ad AH, Gupta SK, Collins MH, et al. An Antibody Against IL-5 Reduces Numbers of Esophageal Intraepithelial Eosinophils in Children with Eosinophilic Esophagitis. Gastroenterology. 2011; 141(5): 1593-1604.
Artem Barski, PhD
Assistant Professor, UC Department of Pediatrics
Epigenetics; epigenomics; immunology; T cell memory
Visit the Barski Lab
Artem Barski, PhD, is interested in epigenetic and transcriptional regulation of gene expression. During his post-doctoral training in Keji Zhao lab at NIH, Dr. Barski took part in the development of ChIP-Seq, a revolutionary method that combines ChIP with the next-generation sequencing. ChIP-Seq allows genome-wide mapping of chromatin modifications and transcription factor binding sites with resolution and sensitivity far exceeding older methods. Together with his NIH colleagues Dr. Barski used this approach to map more than 40 chromatin modifications in human T cells, which fundamentally improved the understanding of epigenetic regulation of transcription. Dr. Barski has since been using ChIP-Seq and other sequencing-based genome-wide methods to understand the role of chromatin modifications in gene regulation. His most recent work includes investigation of chromatin regulation of genes transcribed by RNA Polymerase III and the discovery of gene poising in T cells.
Since his arrival to Cincinnati Children’s Hospital Medical Center in 2011, Dr. Barski is utilizing ChIP-Seq, RNA-Seq and other cutting-edge approaches to understand epigenetic basis of T cell activation, memory and tolerance.
Barski A, Chepelev I, Liko D, Cuddapah S, Fleming AB, Birch J, Cui K, White RJ, Zhao K. Pol II and its associated epigenetic marks are present at Pol III-transcribed noncoding RNA genes. Nat Struct Mol Biol. 2010 May;17(5):629-34. Cuddapah S, Barski A, Zhao K. Epigenomics of T cell activation, differentiation, and memory. Curr Opin Immunol. 2010 Jun;22(3):341-7.
Cuddapah S, Barski A, Cui K, Schones DE, Wang Z, Wei G, Zhao K. Native chromatin preparation and Illumina/Solexa library construction. Cold Spring Harb Protoc. 2009 Jun;2009(6):pdb.prot5237. Barski A, Jothi R, Cuddapah S, Cui K, Roh TY, Schones DE, Zhao K. Chromatin poises miRNA- and protein-coding genes for expression. Genome Res. 2009 Oct;19(10):1742-51
Barski A, Zhao K. Genomic location analysis by ChIP-Seq. J Cell Biochem. 2009 May 1;107(1):11-8. Jothi R, Cuddapah S, Barski A, Cui K, Zhao K. Genome-wide identification of in vivo protein-DNA binding sites from ChIP-Seq data. Nucleic Acids Res. 2008 Sep;36(16):5221-31. Wang Z, Zang C, Rosenfeld JA, Schones DE, Barski A, Cuddapah S, Cui K, Roh TY, Peng W, Zhang MQ, Zhao K. Combinatorial patterns of histone acetylations and methylations in the human genome. Nat Genet. 2008 Jul;40(7):897-903 Schones DE, Cui K, Cuddapah S, Roh TY, Barski A, Wang Z, Wei G, Zhao K. Dynamic regulation of nucleosome positioning in the human genome. Cell. 2008 Mar 7;132(5):887-98. Barski A, Cuddapah S, Cui K, Roh TY, Schones DE, Wang Z, Wei G, Chepelev I, Zhao K. High-resolution profiling of histone methylations in the human genome. Cell. 2007 May 18;129(4):823-37. Barski A, Frenkel B. ChIP Display: novel method for identification of genomic targets of transcription factors. Nucleic Acids Res. 2004 Jul 13;32(12):e104.
Sandy Durrani, MD
MD: Wright State School of Medicine, Dayton, OH.
Residency: Internal Medicine, University of Colorado, Boulder, CO.
Fellowship: Allergy/Immunology, University of Wisconsin, Madison, WI.
Durrani SR, Busse WW. Management of Adolescents and Adults with Asthma. Middleton’s Allergy: Principles and Practice. 8th edition, eds. N. Franklin Adkinson, et al. Elsevier, 902-920. 2014.
Becker TM, Durrani SR, Bochkov YA, Devries MK, Rajamanickam V, Jackson DJ. Effect of exogenous interferons on rhinovirus replication and airway inflammatory responses. Ann Allergy Asthma Immunol. 2013 Nov;111(5):397-401.
Durrani SR, Kelly JT. Pancreatitis as a complication of aspirin desensitization for aspirin-exacerbated respiratory disease. J Allergy Clin Immunol. 2012 Jan;131(1):244-46.
Durrani SR, Montville DJ, Pratt AS, Sahu S, DeVries MK, Rajamanickam V, Gangnon RE, Gill MA, Gern JE, Lemanske RF Jr, Jackson DJ. Innate immune responses to rhinovirus are reduced by the high-affinity IgE receptor in allergic asthmatic children. J Allergy Clin Immunol. 2012 Aug;130(2):489-95.
Durrani SR, Viswanathan RK, Busse WW. What effect does asthma treatment have on airway remodeling? Current perspectives. J Allergy Clin Immunol. 2011 Sep;128(3):439-48.
Zhuang Y, Durrani S, Hodges BD, Dreskin SC, Chen X. Expression of recombinant Ara h 6 in Pichia pastoris but not in Escherichia coli preserves allergic effector function and allows assessment of specific mutations. Mol Nutr Food Res. 2011 June;56(6):986-95.
Durrani SR, Busse WW. Biological therapy for asthma. American College of Chest Physicians: Pulmonary and Critical Care Update. 2011.
Alexandra (Lisa) H. Filipovich, MD Ralph J. Stolle Chair, Clinical Immunology
Ralph J. Stolle Chair, Clinical Immunology
Director, Immune Deficiency and Histiocytosis Program
Medical Director, Diagnostic Immunology Laboratory
Primary immunodeficiencies; BMT for primary immunodeficiencies; hemophagocytic lymphocytosis; post-BMT immune reconstruction
Biology and genetics of hemophagocytic lymphohistiocytosis; investigation of hematopoietic cell transplantation for genetic immunodeficiencies; immunoreconstitution following pediatric stem cell transplantation
Jodele S, Bleesing JJ, Mehta PA, Filipovich AH, Laskin BL, Goebel J, Pinkard SL, Davies SM. Successful early intervention for hyperacute transplant-associated thrombotic microangiopathy following pediatric hematopoietic stem cell transplantation. Pediatr Transplant. 2010 Nov 5.
Marsh RA, Vaughn G, Kim MO, Li D, Jodele S, Joshi S, Mehta PA, Davies SM, Jordan MB, Bleesing JJ, Filipovich AH. Reduced-intensity conditioning significantly improves survival of patients with hemophagocytic lymphohistiocytosis undergoing allogeneic hematopoietic cell transplantation. Blood. 2010 Dec 23;116(26):5824-31. Marsh RA, Bleesing JJ, Filipovich AH. Using flow cytometry to screen patients for X-linked lymphoproliferative disease due to SAP deficiency and XIAP deficiency. J Immunol Methods. 2010 Oct 31;362(1-2):1-9. Laskin BL, Goebel J, Davies SM, Khoury JC, Bleesing JJ, Mehta PA, Filipovich AH, Paff ZN, Lawrence JM, Yin HJ, Pinkard SL, Jodele S. Early clinical indicators of transplant-associated thrombotic microangiopathy in pediatric neuroblastoma patients undergoing auto-SCT. Bone Marrow Transplant. 2010 Aug 9. Filipovich AH, Zhang K, Snow AL, Marsh RA. X-linked lymphoproliferative syndromes: brothers or distant cousins? Blood. 2010 Nov 4;116(18):3398-408. Marsh RA, Madden L, Kitchen BJ, Mody R, McClimon B, Jordan MB, Bleesing JJ, Zhang K, Filipovich AH. XIAP deficiency: a unique primary immunodeficiency best classified as X-linked familial hemophagocytic lymphohistiocytosis and not as X-linked lymphoproliferative disease. Blood. 2010 Aug 19;116(7):1079-82.
Marsh RA, Satake N, Biroschak J, Jacobs T, Johnson J, Jordan MB, Bleesing JJ, Filipovich AH, Zhang K. STX11 mutations and clinical phenotypes of familial hemophagocytic lymphohistiocytosis in North America. Pediatr Blood Cancer. 2010 Jul 15;55(1):134-40.
Filipovich AH. Hemophagocytic lymphohistiocytosis (HLH) and related disorders. Hematology Am Soc Hematol Educ Program. 2009:127-31.
Nicolaou SA, Neumeier L, Takimoto K, Lee SM, Duncan HJ, Kant SK, Mongey AB, Filipovich AH, Conforti L. Differential calcium signaling and Kv1.3 trafficking to the immunological synapse in systemic lupus erythematosus. Cell Calcium. 2010 Jan;47(1):19-28.
Marsh RA, Villanueva J, Kim MO, Zhang K, Marmer D, Risma KA, Jordan MB, Bleesing JJ, Filipovich AH. Patients with X-linked lymphoproliferative disease due to BIRC4 mutation have normal invariant natural killer T-cell populations. Clin Immunol. 2009 Jul;132(1):116-23.
Gene Therapy for SCID-X1 Using Self-Inactivating Gamma. Principal Investigator. National Institutes of Health. Sep 2010-Aug 2015. #U01 AI 087628.
Rare Diseases Clinical Consortia for the Rare Diseases. Principal Investigator. National Institutes of Health. Sep 2009-Aug 2014. #U54 AI 082973.
Hypoxia and potassium channel activity in T Lymphocytes. Principal Investigator. National Institutes of Health. Jun 2009-Jun 2014. #R01 CA 095286.
Fred Finkelman, MD
Rheumatology; cytokine control of immune-mediated disorders and host protection against parasites, cytokine regulation of allergic disorders, cytokine regulation of lymphopoiesis; regulation of cytokine responses and mechanisms of lymphocyte activation and tolerance; anaphylaxis; transfusion-related acute lung injury
Khodoun MV, Strait R, Armstrong L, Yanase N, Finkelman FD. Identification of markers that distinguish IgE- from IgG-mediated anaphylaxis. Proc Natl Acad Sci U S A. 2011 Jul 26;108(30):12413-8.
Strait RT, Mahler A, Hogan S, Khodoun M, Shibuya A, Finkelman FD. Ingested allergens must be absorbed systemically to induce systemic anaphylaxis. J Allergy Clin Immunol. 2011 Apr;127(4):982-9.e1.
Perkins C, Yanase N, Smulian G, Gildea L, Orekov T, Potter C, Brombacher F, Aronow B, Wills-Karp M, Finkelman FD. Selective stimulation of IL-4 receptor on smooth muscle induces airway hyperresponsiveness in mice. J Exp Med. 2011 Apr 11;208(4):853-67.
Brandt EB, Munitz A, Orekov T, Mingler MK, McBride M, Finkelman FD, Rothenberg ME. Targeting IL-4/IL-13 signaling to alleviate oral allergen-induced diarrhea. J Allergy Clin Immunol. 2009 Jan;123(1):53-8.
Herbert Herbert DR, Orekov T, Roloson A, Ilies M, Perkins C, O'Brien W, Cederbaum S, Christianson DW, Zimmermann N, Rothenberg ME, Finkelman FD. Arginase I suppresses IL-12/IL-23p40-driven intestinal inflammation during acute schistosomiasis. J Immunol. 2010 Jun 1;184(11):6438-46.
DR, Yang JQ, Hogan SP, Groschwitz K, Khodoun M, Munitz A, Orekov T, Perkins C, Wang Q, Brombacher F, Urban JF Jr, Rothenberg ME, Finkelman FD. Intestinal epithelial cell secretion of RELM-beta protects against gastrointestinal worm infection. J Exp Med. 2009 Dec 21;206(13):2947-57.
Morris SC, Heidorn SM, Herbert DR, Perkins C, Hildeman DA, Khodoun MV, Finkelman FD. Endogenously produced IL-4 nonredundantly stimulates CD8+ T cell proliferation. J Immunol. 2009 Feb 1;182(3):1429-38. Khodoun M, Strait R, Orekov T, Hogan S, Karasuyama H, Herbert DR, Köhl J, Finkelman FD. Peanuts can contribute to anaphylactic shock by activating complement. J Allergy Clin Immunol. 2009 Feb;123(2):342-51.Forbes EE, Groschwitz K, Abonia JP, Brandt EB, Cohen E, Blanchard C, Ahrens R, Seidu L, McKenzie A, Strait R, Finkelman FD, Foster PS, Matthaei KI, Rothenberg ME, Hogan SP. IL-9- and mast cell-mediated intestinal permeability predisposes to oral antigen hypersensitivity. J Exp Med. 2008 Apr 14;205(4):897-913. Phelan JD, Orekov T, Finkelman FD. Cutting edge: mechanism of enhancement of in vivo cytokine effects by anti-cytokine monoclonal antibodies. J Immunol. 2008 Jan 1;180(1):44-8.
Thomas J. Fischer, MD
Adjunct Professor, UC Department of Pediatrics
Patricia C. Fulkerson, MD, PhD
Eosinophilic disorders; immunodeficiency; immune dysregulation
Visit the Fulkerson Lab web site.
Patricia C. Fulkerson, MD, PhD, is an assistant professor of pediatrics at Cincinnati Children’s Hospital Medical Center and the University of Cincinnati College of Medicine. Her PhD under the mentorship of Dr. Marc Rothenberg was focused on the analysis of experimental allergic lung inflammation in mice. She made a series of groundbreaking observations including a novel approach to understanding the complex and coordinated interplay of the chemokine family of cytokines and eosinophils in experimental allergic lung disease. Throughout her graduate studies, Dr. Fulkerson was recognized as a top trainee in the laboratory. Nationally, she was selected for competitive awards; her most distinguished award was the Serono Ian Clark-Lewis Memorial Award, provided to a trainee for the best talk at the Keystone Symposium Chemokines & Chemokine Receptors. Locally, she has received several competitive awards and scholarships including the Physician Scientist Training Program Scholar Award, as well as prizes for participation in research forums. Upon completion of the MD/PhD program, Dr. Fulkerson completed a research-track pediatric residency. She was recognized as being an outstanding resident and was awarded the Thomas F. Boat Pediatric Pulmonology Award in her final year of residency.
Dr. Fulkerson's innovation and dedication to research continued to be recognized during her allergy/immunology fellowship; she received the AAI-Life Technologies Trainee Achievement Award from the American Association of Immunologists in 2011, and she has the distinction of having achieved extramural funding during her first year of clinical fellowship, with the NIH awarding her a K08 grant on her first application. This independent funding at such an early stage is a notable accomplishment. Now, as an assistant professor, Dr. Fulkerson’s independent research program is focused on the biology of the eosinophil lineage-committed progenitor (EoP). Her overall aim is to identify novel therapeutic targets to block eosinophil production for the treatment of patients with eosinophilic disorders. She has developed a number of innovative methods to study the regulation of eosinophil development including liquid culture systems to follow differentiation of both murine and human EoPs into mature effector eosinophils. The pathways that are identified in her culture systems are tested in models of hypereosinophilia, infection, and allergic inflammation to further characterize the clinical and therapeutic potential of candidate targets.
MD: Medical Scientist Training Program, University of Cincinnati College of Medicine, Cincinnati, OH, 2007.
PhD: Molecular Genetics, Microbiology & Immunology, University of Cincinnati College of Medicine, Cincinnati, OH, 2005.
Residency: Pediatrics, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, 2010.
Fellowship: Allergy and Immunology, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, 2012.
Wechsler ME, Fulkerson PC, Bochner BS, Gauvreau GM, Gleich GJ, Henkel T, Kolbeck R, Mathur SK, Ortega H, Patel J, Prussin C, Renzi P, Rothenberg ME, Roufosse F, Simon D, Simon HU, Wardlaw A, Weller PF, Klion AD. Novel targeted therapies for eosinophilic disorders. J Allergy Clin Immunol. 2012;130(3):563-71.
Zuo L, Fulkerson PC, Finkelman FD, Mingler M, Fischetti CA, Blanchard C, Rothenberg ME. IL-13 induces esophageal remodeling and gene expression by an eosinophil-independent, IL-13R alpha 2-inhibited pathway. J Immunol. 2010;185(1):660-9.
Fulkerson PC, Rothenberg ME. Origin, regulation and physiological function of intestinal eosinophils. Best Pract Res Clin Gastroenterol. 2008;22(3):411-23.
Mishra A, Wang M, Pemmaraju VR, Collins MH, Fulkerson PC, Abonia JP, Blanchard C, Putnam PE, Rothenberg ME. Esophageal remodeling develops as a consequence of tissue specific IL-5-induced eosinophilia. Gastroenterology. 2008;134(1):204-14.
Fulkerson PC, Fischetti CA, Rothenberg ME. Eosinophils and CCR3 regulate interleukin-13 transgene-induced pulmonary remodeling. Am J Pathol. 2006;169(6):2117-26.
Fulkerson PC, Fischetti CA, McBride ML, Hassman LM, Hogan SP, Rothenberg ME. A central regulatory role for eosinophils and the eotaxin/CCR3 axis in chronic experimental allergic airway inflammation. Proc Natl Acad Sci U S A. 2006;103(44):16418-23.
Blanchard C, Wang N, Stringer KF, Mishra A, Fulkerson PC, Abonia JP, Jameson SC, Kirby C, Konikoff MR, Collins MH, Cohen MB, Akers R, Hogan SP, Assa'ad AH, Putnam PE, Aronow BJ, Rothenberg ME. Eotaxin-3 and a uniquely conserved gene-expression profile in eosinophilic esophagitis. J Clin Invest. 2006;116(2):536-47.
Fulkerson PC, Zhu H, Williams DA, Zimmermann N, Rothenberg ME. CXCL9 inhibits eosinophil responses by a CCR3- and Rac2-dependent mechanism. Blood. 2005;106(2):436-43.
Fulkerson PC, Zimmermann N, Brandt EB, Muntel EE, Doepker MP, Kavanaugh JL, Mishra A, Witte DP, Zhang H, Farber JM, Yang M, Foster PS, Rothenberg ME. Negative regulation of eosinophil recruitment to the lung by the chemokine monokine induced by IFN-gamma (Mig, CXCL9). Proc Natl Acad Sci U S A. 2004;101(7):1987-92.
Gurjit Khurana Hershey, MD, PhD Director, Division of Asthma Research
Director, Division of Asthma Research
Co-Director, Office of Pediatric Clinical Fellowships
Asthma; allergic rhinitis; food allergy; urticaria
Genetics of allergy and asthma; cytokines; signaling pathways
Visit the Khurana Hershey Lab.
Gurjit Khurana Hershey, MD, PhD, received a BS degree from the University of Iowa, and MD and PhD degrees from Washington University School of Medicine. After completing pediatric residency and an allergy/immunology Fellowship at St. Louis Children’s Hospital, Dr. Khurana Hershey joined the faculty at Cincinnati Children’s Hospital Medical Center. She now directs the Division of Asthma Research at Cincinnati Children’s Hospital Medical Center and is the director of the Medical Scientist Training Program at the University of Cincinnati College of Medicine.
In addition to her clinical duties, Dr. Khurana Hershey directs an NIH-funded research program focused on the genetics and genomics of allergic inflammation with a focus on cytokines and signal transduction. Her research has been continuously funded for over fifteen years. She is the principal investigator of an NIH-funded Asthma and Allergic Diseases Cooperative Research Center (AADCRC), and is also the PI of the Inner City Asthma Consortium, an NIH funded subcontract. She is the PI of the UC T32 MSTP training grant. In addition to her research contributions, she is an outstanding clinician and teacher/mentor. Several of her trainees now hold academic faculty positions. She is the recipient of the 2013 Cincinnati Children’s Educational Achievement Award.
Dr. Khurana Hershey is a fellow of the American Pediatric Society and the American Academy of Allergy, Asthma and Immunology. She serves on the Executive Council of the American Academy of Asthma, Allergy and Immunology Program Committee, is the Chair of the Grant Review Committee and appointed Vice Chair of the Basic and Immunology Interest Section. She is a member of the Editorial Board of the Journal of Allergy and Clinical Immunology. She was recently named One of the Five Leading Women in Healthcare in the Greater Cincinnati Metropolitan Area, and Outstanding Woman at Cincinnati Children’s Hospital Medical Center.
BS: University of Iowa, Iowa City, IA, 1985.PhD: Washington University School of Medicine, St. Louis, MO, 1990.
MD: Washington University School of Medicine, St. Louis, MO, 1992. Residency: St. Louis Children's Hospital, St. Louis, MO, 1992-1995. Fellowship: St. Louis Children's Hospital, St. Louis, MO, 1995-1997.
Board Certification: American Board of Pediatrics, 2009 - Present.
Board Certification: American Board of Allergy and Immunology, 2008 - Present.
Biagini Myers JM, Martin LJ, Butsch Kovacic M, Mersha TB, He H, Pilipenko V, Lindsey MA, Ericksen MB, Bernstein DI, LeMasters GK, Lockey JE, Khurana Hershey GK. Epistasis between serine protease inhibitor Kazal-type 5 (SPINK5) and thymic stromal lymphopoietin (TSLP) genes contributes to childhood asthma. J Allergy Clin Immunol. 2014 May 13. pii: S0091-6749(14)00520-X.
Wood RA, Togias A, Wildfire J, Visness CM, Matsui EC, Gruchalla R, Hershey G, Liu AH, O’Connor GT, Pongracic JA, Zoratti E, Little F, Granada M, Kennedy S, Durham SR, Shamji MH, Busse WW. Development of cockroach immunotherapy by the Inner-City Asthma Consortium. J Allergy Clin Immunol. 2014 Mar;133(3)846-52.
Zhang Z, Xiao C, Gibson AM, Bass SA, Khurana Hershey GK. EGFR signaling blunts allergen-induced IL-6 production and Th17 responses in the skin and attenuates development and relapse of atopic dermatitis. J Immunol. 2014 Feb 1:192(3):859-66.
Kinker KG, Gibson AM, Bass SA, Day BP, Deng, J, Medvedovic M, Figueroa JA, Hershey GK, Chen W. Overexpression of dimethylarginine dimethylaminohydrolase 1 attenuates airway inflammation in a mouse model of asthma. PloS One. 2014 Jan 10;9 (1):e85148.
Acciani TH, Brandt EB, Khurana Hershey GK, Le Cras TD. Diesel exhaust particle exposure increases severity of allergic asthma in young mice and children. Clin Exp Allergy. 2013 Dec;43(12):1406-18.
Brandt EB, Kovacic MB, Lee GB, Gibson AM, Acciani TH, Le Cras TD, Budelsky AL, Khurana Hershey GK. Diesel exhaust particle induction of IL17A contributes to severe asthma. J Allergy Clin Immunol. 2013 Nov:132(5);1194-1204.
Brandt EB, Gibson AM, Bass S, Khurana Hershey GK. Exacerbation of Allergen-Induced Eczema in TLR4- and TRIF-Deficient Mice. J Immunol. 2013 Oct 1;191(7):3519-25.
Chen W, Sivaprasad U, Gibson AM, Ericksen MB, Cunningham CM, Bass SA, Kinker KG, Finkelman FD, Wills-Karp M, Khurana Hershey GK. IL-13 receptor α2 contributes to development of experimental allergic asthma. J Allergy Clin Immunol. 2013 Oct;132(4):951-958.
Lee GB, Brandt EB, Xiao C, Gibson AM, Le Cras TD, Brown LA, Fitzpatrick AM, Khurana Hershey GK. Diesel exhaust particles induce cysteine oxidation and S-glutathionylation in house dust mite induced murine asthma. PLoS One. 2013;8(3):e60632.
Mintz-Cole RA, Brandt EB, Bass SA, Gibson AM, Reponen T, Khurana Hershey GK. Surface availability of beta-glucans is critical determinant of host immune response to C. cladosporioides. J Allergy Clin Immunol. 2013 Jul;132(1):159-69.
Simon P. Hogan, PhD Director of Research, Division of Allergy and Immunology
Director of Research, Division of Allergy and Immunology
Director of Admissions, Immunology Graduate Program
Food allergies and anaphylaxis; inflammatory bowel diseases (IBD); innate immunity; gastrointestinal immunity and function; cystic fibrosis (CF)
Visit the Hogan Lab.
Waddell A, Ahrens R, Tsai YT, Sherrill JD, Denson LA, Steinbrecher KA, Hogan SP. Intestinal CCL11 and eosinophilic inflammation is regulated by myeloid cell-specific RelA/p65 in mice. J Immunol. 2013 May 1;190(9):4773-85.
Ahrens R, Osterfeld H, Wu D, Arumugam M, Groschwitz K, Strait RA, Finkelman FD, Hogan SP. Intestinal mast cell levels influence severity of oral antigen-induced anaphylaxis. Am J Pathol. 2012 Apr;180(4):1535-46.
Beichler A, Ahrens R, Steinbrecher K, Rothenberg ME, Munitz A, Denson L, Hogan SP. Colonic eosinophilic inflammation in experimental colitis is mediated by Ly6C+ CCR2+ inflammatory monocyte-derived CCL11. J Immunol. 2011 May 15;186(10):5993-6003.
Arumugam M, Ahrens R, Osterfeld H, Kottyan LC, Shang X, Maclennan JA, Zimmermann N, Zheng Y, Finkelman FD, Hogan SP. Increased susceptibility of 129SvEvBrd mice to IgE-Mast cell mediated anaphylaxis. BMC Immunol. 2011 Feb 3;12:14.
Wu D, Ahrens R, Osterfeld H, Noah TK, Groschwitz K, Foster PS, Steinbrecher KA, Rothenberg ME, Shroyer NF, Matthaei KI, Finkelman FD, Hogan SP. Interleukin-13 (IL-13)/IL-13 receptor alpha1 (IL-13Ralpha1) signaling regulates intestinal epithelial cystic fibrosis transmembrane conductance regulator channel-dependent Cl- secretion. Journal of Biological Chemistry. 2011;286(15), 13357-13369.
Osterfeld H, Ahrens R, Strait R, Rothenberg ME, Finkelman FD, Renauld JC, Hogan SP. Divergent roles for the IL9/IL9R-pathway in systemic antigen- and oral antigen-induced anaphylaxis. J Allergy Clin Immunol. 2010;125: 469-476.
Munitz A, Cole ET, Waddell A, Groschwitz K, Ahrens R, Steinbrecher K, Willson T, Han X, Denson L, Rothenberg ME, Hogan SP. Paired immunoglobulin-like receptor B (PIR-B) negatively regulates macrophage activation in experimental colitis. Gastroenterology. 2010;139(2), 530-541.
Groschwitz K, Ahrens R, Osterfeld H, Gurish MF, Abrink M, Finkelman F, Pejler G, Hogan SP. Mast cells regulate homeostatic intestinal epithelial migration and barrier function by a chymase/Mcpt4-dependent mechanism. Proceedings of the National Academy of Sciences of the United States of America. 2009;106(52), 22381-22386.
Ahrens R, Waddell A, Seidu L, Blanchard, C, Carey R, Forbes E, Lampinen M, Willson T, Cohen E, Stringer K, Ballard E, Munitz A, Xu H, Lee N, Lee JJ, Rothenberg ME, Denson L, Hogan SP. Intestinal macrophage/epithelial cell-derived CCL11/eotaxin-1 mediates eosinophil recruitment and function in pediatric ulcerative colitis. The Journal of Immunology. 2008;181(10), 7390-7399.
Forbes EE, Groschwitz K, Abonia JP, Brandt EB, Cohen E, Blanchard C, Ahrens R, Seidu L, McKenzie A, Strait R, Finkelman FD, Foster PS, Matthaei KI, Rothenberg ME, Hogan SP. IL-9- and mast cell-mediated intestinal permeability predisposes to oral antigen hypersensitivity. The Journal of Experimental Medicine. 2008;205(4), 897-913.
MiR-375 regulation of CFTR expression and Cl- secretory function. Principal Investigator. Cystic Fibrosis Foundation. Jul 2012-Jun 2014.
Eosinophil:M2 Macrophage:CCL11 Axis in Experimental Colitis and Pediatric Corticosteroid Resistant UC. Principal Investigator. National Institutes of Health/National Institute of Diabetes and Digestive and Kidney Diseases (NIH/NIDDK). Apr 2012-Mar 2016.
Epithelial Genes in Allergic Inflammation. Project 2 – Collaborating Investigator. National Institutes of Health/National Institute of Allergy and Infectious Diseases (NIH/NIAIDS). Sep 2006-Aug 2016.
Michelle B. Lierl, MD Clinical Allergist, Division of Allergy and Immunology
Clinical Allergist, Division of Allergy and Immunology
Treatment and prevention of asthma; allergic rhinitis; allergen immunotherapy; eczema; food allergy; anaphylaxis; suspected immune deficiency
Role of environmental allergens and pollutants in childhood asthma; allergen immunotherapy; asthma pathogenesis and treatment; role of outdoor fungal spores as aeroallergens; diagnosis and treatment of food allergy
Visit Dr. Lierl's fungal spore photo website.
Visit the Lierl Lab website.
Michelle B. Lierl, MD, is board-certified in pediatrics, pediatric pulmonary medicine and allergy/immunology. Dr. Lierl's primary clinical interests are diagnosis and treatment of asthma, allergic rhinitis, chronic cough, food, latex, insect venom and drug allergies, and eczema.
Dr. Lierl has been treating allergy patients in the Allergy Clinic and Asthma Center, which provides state-of-the-art diagnosis and treatment of asthma and allergies, as well as comprehensive patient education regarding these diseases. She has developed community outreach and patient / family education programs for urban children with asthma and their families.
Dr. Lierl also helps staff the allergy inpatient service, which provides consultation for the management of patients with difficult-to-manage asthma, suspected drug allergies, anaphylaxis, or suspected immune deficiency.
Lierl MB. Management of mild to moderate pediatric asthma. Infect Dis Child. 2011 Dec;supplement: 8-12.
Lierl MB. Allergen immunotherapy: Shots for asthma, wheezing and bee sting. Ped Annals. 2011 Apr;40:192-199.
Spanier AJ, Kahn RS, Hurnung RW, Lierl MB, Lanphear BP. Associations of Fraction of Exhaled Nitric Oxide with Beta Agonist Use in Children with Asthma. Pediatric Allergy, Immunology, and Pulmonology. 2011 Mar;24(1):45-50.
Lanphear BP, Hornung RW, Khoury J, Yolton K, Lierl M, Kalkbrenner A. Effects of HEPA air cleaners on unscheduled asthma visits and asthma symptoms for children exposed to secondhand tobacco smoke. Pediatrics. 2011 Jan;127(1):93-101.
Metz KA, Assa'ad A, Lierl MB, Backeljauw P. Allergic reaction to mecasermin. Ann Allergy Asthma Immunol. 2009;103(1):82-3.
Metz KA, Johnson T, Khurana Hershey GK, Lierl MB, Seidu L, Burns K, Assa’ad A. Successful administration of cytarabine in a 16 month old girl with acute myelogenous leukemia and cytarabine syndrome. Ann Allergy, Asthma Immunol. 2009;102:173-4.
Spanier AJ, Kahn RS, Hornung RW, Wang N, Sun G, Lierl MB, Lanphear BP. Environmental exposures, nitric oxide synthase genes, and exhaled nitric oxide in asthmatic children. Pediatr Pulmonol. 2009 Aug;44(8):812-9.
Spanier AJ, Hornung RW, Kahn RS, Lierl MB, Lanphear BP. Seasonal variation and environmental predictors of exhaled nitric oxide in children with asthma. Pediatr Pulmonol. 2008 Jun;43(6):576-83.
Lierl M. Periodic fever syndromes: a diagnostic challenge for the allergist. Allergy. 2007 Dec;62(12):1349-58. Review.
Spanier AJ, Hornung R, Lierl M, Lanphear BP. Environmental exposures and exhaled nitric oxide in children with asthma. J Pediatr. 2006 Aug;149(2):220-6.
Kimberly A. Risma, MD, PhD Director, Allergy and Immunology Fellowship Program
Director, Allergy and Immunology Fellowship Program
Immune deficiency; immune dysregulation
Pathophysiology of perforin missense mutations identified in individuals with hemophagocytic lymphohistiocytosis; molecular mechanisms of primary immune deficiency and dysregulation; natural killer cell and cytotoxic T lymphocyte cytotoxicity
Visit the Risma Lab website.
Kimberly Risma, MD, PhD, is an assistant professor in the Division of Allergy and Immunology at Cincinnati Children’s and the University of Cincinnati College of Medicine.
Dr. Risma graduated magna cum laude with a Bachelor of Arts in Chemistry from Duke University in 1990 and was elected into The Phi Beta Kappa Society. She then matriculated at Case Western Reserve University (CWRU) School of Medicine in the Medical Scientist Training Program (MSTP). In 1996, she completed a PhD in pharmacology. She was selected by the leadership of the CWRU MSTP as the recipient of the 1997 Martin Wahl Memorial Fund Award, given annually to recognize the graduating MD, PhD student who has demonstrated the highest level of independence in research and excellence in research and clinical skills. She was also elected to Alpha Omega Alpha Society in 1997.
In 1997, she enrolled in a Pediatrics residency at Cincinnati Children’s Hospital Medical Center/University of Cincinnati. During the residency program, Dr. Risma was awarded the pediatric resident teaching award by the medical students. She also engaged in translational research studies related to the genetics of asthma under the mentorship of Dr. Gurjit Hershey, resulting in a first author publication as a pediatric resident.
In 2000, Dr. Risma was accepted to the Allergy and Immunology Fellowship Program at Cincinnati Children’s. In addition to her clinical training, she pursued an innovative research project under the mentorship of Dr. Janos Sumegi and Dr. Alexandra Filipovich. She proposed a mechanism to study the structural and functional impact of perforin missense mutations identified in patients with hemophagocytic lymphohistiocytosis. In 2004 she was awarded the Nezelof Prize for best scientific presentation at the international meeting of the Histiocyte Society. The culmination of her fellowship research project was published in the Journal of Clinical Investigation, 2006.
Upon completion of her fellowship in 2005, Dr. Risma was appointed as an Assistant Professor in the Division of Allergy and Immunology at Cincinnati Children’s Hospital Medical Center. In 2006 Dr. Risma received a Clinical Scientist Development Award from the Doris Duke Charitable Foundation. Dr. Risma is the director of the Allergy and Immunology Fellowship Program at Cincinnati Children's, having served in this leadership position since August of 2012.Dr. Risma's research program focuses on understanding the molecular mechanisms of immunodeficiency and immune dysregulation in children, especially as it relates to disorders of lymphocyte cytotoxicity. In addition to her research, she sees patients from all around the country in consultation for primary immune deficiency, immune dysregulation, and allergic disorders.
MD: Case Western Reserve University School of Medicine, Cleveland, OH, 1997.
PhD: Case Western Reserve University School of Medicine, Cleveland, OH, 1996.
Residency: Pediatrics, Cincinnati Children's Hospital Medical Center, 1997-2000.
Fellowship: Allergy / Immunology, Cincinnati Children's Hospital Medical Center.
Certification: Pediatrics, 2007; Allergy and Immunology, 2005.
Risma K. A loss of naivete. Blood. 2012 Apr 12;119(15):3371-2.
Risma K, Jordan MB. Hemophagocytic lymphohistiocytosis: updates and evolving concepts. Curr Opin Pediatr. 2012 Feb;24(1):9-15.
Uygungil B, Assa'Ad A, Khurana Hershey GK, Risma K. Immunodeficiency: a problem with the faucet or the drain? Ann Allergy Asthma Immunol. 2011 Dec;107(6):547-9.
Zhang K, Jordan MB, Marsh RA, Johnson JA, Kissell D, Meller J, Villanueva J, Risma KA, Wei Q, Klein PS, Filipovich AH. Hypomorphic mutations in PRF1, MUNC13-4, and STXBP2 are associated with adult-onset familial HLH. Blood. 2011 Nov 24;118(22):5794-8.
Lykens JE, Terrell CE, Zoller EE, Risma K, Jordan MB. Perforin is a critical physiologic regulator of T-cell activation. Blood. 2011 Jul 21;118(3):618-26.
Sumegi J, Barnes MG, Nestheide SV, Molleran-Lee S, Villanueva J, Zhang K, Risma KA, Grom AA, Filipovich AH. Gene expression profiling of peripheral blood mononuclear cells from children with active hemophagocytic lymphohistiocytosis. Blood. 2011 Apr 14;117(15):e151-60.
Uygungil B, Bleesing JJ, Risma KA, McNeal MM, Rothenberg ME. Persistent rotavirus vaccine shedding in a new case of severe combined immunodeficiency: A reason to screen. J Allergy Clin Immunol. 2010 Jan;125(1):270-1.
Marsh RA, Villanueva J, Kim MO, Zhang K, Marmer D, Risma KA, Jordan MB, Bleesing JJ, Filipovich AH. Patients with X-linked lymphoproliferative disease due to BIRC4 mutation have normal invariant natural killer T cell populations. Clin Immunol. 2009 Jul;132(1):116-23.
Marsh RA, Villanueva J, Zhang K, Snow AL, Su HC, Madden L, Mody R, Kitchen B, Marmer D, Jordan MB, Risma KA, Filipovich AH, Bleesing JJ. A rapid flow cytometric screening test for X-linked lymphoproliferative disease due to XIAP deficiency. Cytometry B Clin Cytom. 2009 Sep;76(5):334-44.
Risma KA, Frayer RW, Filipovich AH, Sumegi J. Aberrant maturation of mutant perforin underlies the clinical diversity of hemophagocytic lymphohistiocytosis. J Clin Invest. 2006 Jan;116(1):182-92.
Marc E. Rothenberg, MD, PhD Director, Division of Allergy and Immunology
Director, Division of Allergy and Immunology
Director, Cincinnati Center for Eosinophilic Disorders
Eosinophilia; eosinophilic disorders; asthma; allergy; food allergy
Visit the Rothenberg Lab.
Dr. Rothenberg is director of the Division of Allergy/Immunology at Cincinnati Children's Hospital Medical Center and tenured professor of pediatrics at Cincinnati Children’s and University of Cincinnati College of Medicine. He graduated summa cum laude with highest honors in chemistry and biochemistry from Brandeis University. He then completed the MD/PhD program at Harvard Medical School under Dr. Frank Austen, conducting studies on eosinophil hematopoiesis, as he developed the first culture system for human eosinophils. After completing residency at Children’s Hospital, Boston, Dr. Rothenberg did a fellowship in allergy/immunology and hematology at Children’s Hospital. Dr. Rothenberg did post-doctorate training with Dr. Philip Leder, Harvard Medical School, where he cloned the eotaxin chemokine. After being faculty at Harvard Medical School for one year, he came to the University of Cincinnati and Cincinnati Children's, where he has helped build a top program in research, and his division is a leader in allergy and immunology.
His research is focused on molecular analysis of allergic inflammation, primarily on the molecular pathogenesis of eosinophilic esophagitis. His laboratory takes a multi-disciplinary approach including the development of preclinical murine models: genetics, genomics, molecular immunology, and biochemistry. Dr. Rothenberg’s awards include the 2007 E Mead Johnson Award from the Society of Pediatric Research, 2010 National Institutes of Health MERIT Award, and being elected an American Association for the Advancement of Science fellow. He is a member of the American Society for Clinical Investigation, American Academy of Pediatrics, and Society for Pediatric Radiology. His publications number over 300. He has served on review panels for journals/grant agencies including National Institutes of Health (NIH), Burroughs Trust, and Medical Research Council of the United Kingdom. He served for four-years on the Advisory Council of National Institute of Allergy and Infectious Disease. He has been associate editor of the Journal of Allergy and Clinical Immunology since 2004. His research has been supported by sources including the NIH, Human Frontier Science Program Organization, Burroughs Wellcome Fund, Dana Foundation, and Department of Defense.
Visit the Rothenberg Lab web site.
MD, PhD: Harvard Medical School, Cambridge, MA, 1990.
Residency: Pediatrics, Children's Hospital, Boston, MA, 1991-1992.
Fellowship: Immunology / Allergy, Children's Hospital, Boston, MA, 1992-1994; Hematology / Oncology, Children's Hospital and Dana Farber Cancer Institute, Boston, MA, 1992-1995.
Certification: National Board of Medical Examiners, 1991; Board of Registration in Medicine, MA, 1992; American Board of Pediatrics, 1995, 2001, 2008; Ohio State Medical Board, 1997; American Board of Allergy and Immunology, 1997, 2006.
Butz BK, Wen T, Gleich GJ, Furuta GT, Spergel J, King E, Kramer RE, Collins MH, Stucke E, Mangeot C, Jackson WD, O'Gorman M, Abonia JP, Pentiuk S, Putnam PE, Rothenberg ME. Efficacy, dose reduction, and resistance to high-dose fluticasone in patients with eosinophilic esophagitis. Gastroenterology. 2014; In press.
Sherrill JD, Kc K, Wu D, Djukic Z, Caldwell JM, Stucke EM, Kemme KA, Costello MS, Mingler MK, Blanchard C, Collins MH, Abonia JP, Putnam PE, Dellon ES, Orlando RC, Hogan SP, Rothenberg ME. Desmoglein-1 regulates esophageal epithelial barrier function and immune responses in eosinophilic esophagitis. Mucosal Immunol. 2014 May;7(3):718-29.
Wen T, Stucke EM, Grotjan TM, Kemme KA, Abonia JP, Putnam PE, Franciosi JP, Garza JM, Kaul A, King EC, Collins MH, Kushner JP, Rothenberg ME. Molecular diagnosis of eosinophilic esophagitis by gene expression profiling. Gastroenterology. 2013 Dec;145(6):1289-99.
Wen T, Besse JA, Mingler MK, Fulkerson PC, Rothenberg ME. Eosinophil adoptive transfer system to directly evaluate pulmonary eosinophil trafficking in vivo. Proc Natl Acad Sci U S A. 2013 Apr 9;110(15):6067-72
Lu TX, Sherrill JD, Wen T, Plassard AJ, Besse JA, Abonia JP, Franciosi JP, Putnam PE, Eby M, Martin LJ, Aronow BJ, Rothenberg ME. MicroRNA signature in patients with eosinophilic esophagitis, reversibility with glucocorticoids, and assessment as disease biomarkers. J Allergy Clin Immunol. 2012 Apr;129(4):1064-75.e9.
Rothenberg ME, Spergel JM, Sherrill JD, Annaiah K, Martin LJ, Cianferoni A, Gober L, Kim C, Glessner J, Frackelton E, Thomas K, Blanchard C, Liacouras C, Verma R, Aceves S, Collins MH, Brown-Whitehorn T, Putnam PE, Franciosi JP, Chiavacci RM, Grant SF, Abonia JP, Sleiman PM, Hakonarson H. Common variants at 5q22 associate with pediatric eosinophilic esophagitis. Nat Genet. 2010 Apr;42(4):289-91.
Rothenberg ME, Klion AD, Roufosse FE, Kahn JE, Weller PF, Simon HU, Schwartz LB, Rosenwasser LJ, Ring J, Griffin EF, Haig AE, Frewer PI, Parkin JM, Gleich GJ; Mepolizumab HEC Study Group. Treatment of patients with the hypereosinophilic syndrome with mepolizumab. N Engl J Med. 2008 Mar 20;358(12):1215-28.
Blanchard C, Wang N, Stringer KF, Mishra A, Fulkerson PC, Abonia JP, Jameson SC, Kirby C, Konikoff MR, Collins MH, Cohen MB, Akers R, Hogan SP, Assa'ad AH, Putnam PE, Aronow BJ, Rothenberg ME. Eotaxin-3 and a uniquely conserved gene-expression profile in eosinophilic esophagitis. J Clin Invest. 2006 Feb;116(2):536-47.
Hogan SP, Mishra A, Brandt EB, Royalty MP, Pope SM, Zimmermann N, Foster PS, Rothenberg ME. A pathological function for eotaxin and eosinophils in eosinophilic gastrointestinal inflammation. Nat Immunol. 2001 Apr;2(4):353-60.
Mishra A, Hogan SP, Brandt EB, Rothenberg ME. An etiological role for aeroallergens and eosinophils in experimental esophagitis. J Clin Invest. 2001 Jan;107(1):83-90.
NICHHD Pediatric Center for Gene Expression and Developmental Sciences. Training Director. National Institutes of Health. Dec 2011–Nov 2016. K12 HD028827.
Epithelial Genes in Allergic Inflammation. Co-Investigator. National Institutes of Health. Sep 2011–Aug 2016. U19 AI070235.
Eosinophil:M2 Macrophage:CCL11 Axis in Experimental Colitis and Pediatric Corticosteroid Resistant Ulcerative Colitis. Co-Investigator. National Institutes of Health. Apr 2012–Mar 2016. R01 DK090119-01A1.
Immunobiology of Peanut Allergy and It’s Treatment. Co-Investigator. National Institutes of Health. Jul 2010–Jun 2015. U19 AI066738.
Regulation of Gastrointestinal Eosinophils. Principal Investigator. National Institutes of Health. Dec 2009–Nov 2014. R37 AI045898.
Cincinnati Center for Clinical and Translational Science and Training. Co-Program Director. National Institutes of Health. Apr 2009–Mar 2015. KL2 TR000078.
The Expression and Function of Paired Immunoglobulin-like Receptor B in Eosinophils. Co-Principal Investigator. U.S. - Israel Binational Science Foundation. Oct 2012–Sep 2016. #201144.
Yui-Hsi Wang, PhD
Wang YH, Voo KS, Liu B, Chen CY, Uygungil B, Spoede W, Bernstein JA, Huston DP, Liu YJ. A novel subset of CD4(+) T(H)2 memory/effector cells that produce inflammatory IL-17 cytokine and promote the exacerbation of chronic allergic asthma. J Exp Med. 2010 Oct 25;207(11):2479-91.
Shaw J, Wang YH, Ito T, Arima K, Liu YJ. Plasmacytoid dendritic cells regulate B-cell growth and differentiation via CD70. Blood. 2010 Apr 15;115(15):3051-7. Wang YH, Liu YJ. Thymic stromal lymphopoietin, OX40-ligand, and interleukin-25 in allergic responses. Clin Exp Allergy. 2009 Jun;39(6):798-806. Voo KS, Wang YH, Santori FR, Boggiano C, Wang YH, Arima K, Bover L, Hanabuchi S, Khalili J, Marinova E, Zheng B, Littman DR, Liu YJ. Identification of IL-17-producing FOXP3+ regulatory T cells in humans. Proc Natl Acad Sci U S A. 2009 Mar 24;106(12):4793-8. Lu N, Wang YH, Wang YH, Arima K, Hanabuchi S, Liu YJ. TSLP and IL-7 use two different mechanisms to regulate human CD4+ T cell homeostasis. J Exp Med. 2009 Sep 28;206(10):2111-9. Esashi E, Wang YH, Perng OA, Qin XF, Hennighausen L, Liu YJ, Watowich SS. Differential regulation of plasmacytoid and conventional dendritic cell development by GM-CSF through STAT5. Immunity. 2008;28:1-12. Wang YH, Liu YJ. The IL-17 cytokine family and their role in allergic inflammation. Curr Opin Immunol. 2008 Dec;20(6):697-702. Wang YH, Liu YJ. OX40-OX40L interactions: a promising therapeutic target for allergic diseases?J Clin Invest. 2007 Dec;117(12):3655-7.
Wang YH, Angkasekwinai P, Meng Q, Lu N, Voo KS, Arima K, Hanabuchi S, Corrigan CG, Lee T, Dong C, Huston DR, Yao Z, Ying S, and Liu YJ. IL-25 mediated cross talk between eosinophils and TSLP-DC-activated TH2 memory cells augments allergic immune responses. J. Exp. Med. 2007;204(8): 1837-1847. Ito T, Wang YH, Duramad O, Hanabuchi S, Perng OA, Gilliet M, Qin FX, Liu YJ. OX40 ligand shuts down IL-10-producing regulatory T cells. Proc Natl Acad Sci U S A. 2006 Aug 29;103(35):13138-43.
The roles of IL-17-producing TH2 memory/effector cells in allergic asthma. Principal Investigator. American Lung Association. July 2010 - June 2012. #AI-169584-N.
Regulation and maintenance of TH2 memory/effector cells. Principal Investigator. National Institutes of Health. May 2010- April 2015. #R01AI090129-01.
3333 Burnet Avenue, Cincinnati, Ohio 45229-3026 | 1-513-636-4200 | 1-800-344-2462 | TTY:1-513-636-4900
New to Cincinnati Children’s or live outside of the Tristate area? 1-877-881-8479
© 1999-2014 Cincinnati Children's Hospital Medical Center